Preparation, characterization and evaluation of [125I]-pirarubicin: a new therapeutic agent for urinary bladder cancer with potential for use as theranostic agent
OA El-Kawy, G Abdelaziz - Applied Radiation and Isotopes, 2022 - Elsevier
Improving urinary bladder cancer diagnosis, follow-up, and therapy tools to overcome
existing limitations and increase survival rates is a highly desirable goal. In the current
investigation, pirarubicin, a new generation antineoplastic anthracycline, was labeled with
[125 I] via an electrophilic substitution reaction. The reaction parameters were studied to
optimize the iodination process. The labeled compound showed high radiochemical yield
(98.5±2.1%) and consistently remained above 90% for more than 20 h at room temperature …
existing limitations and increase survival rates is a highly desirable goal. In the current
investigation, pirarubicin, a new generation antineoplastic anthracycline, was labeled with
[125 I] via an electrophilic substitution reaction. The reaction parameters were studied to
optimize the iodination process. The labeled compound showed high radiochemical yield
(98.5±2.1%) and consistently remained above 90% for more than 20 h at room temperature …
以上显示的是最相近的搜索结果。 查看全部搜索结果